Stay updated on Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added and the funding-status notice was removed, representing a minor site maintenance update that does not affect the trial details or user actions on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a site-wide Notice about a lapse in government funding with directions to cc.nih.gov and opm.gov. Updated the page to Revision: v3.4.1, replacing v3.4.0.SummaryDifference0.4%

- Check28 days agoChange DetectedMinor editorial updates include capitalization tweaks for QC terminology, a new 'Show glossary' option, and a revision tag (v3.4.0) replacing the previous version.SummaryDifference0.2%

- Check42 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

- Check64 days agoChange DetectedThe page now includes an expanded Locations section with new study sites in Pordenone and Turin, updating where the trial is conducted. The footer item HHS Vulnerability Disclosure was removed (a minor change) and the revision updated to v3.3.3.SummaryDifference0.3%

- Check85 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2; no changes to core content or user-facing data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Maintenance in Unresectable Stage III NSCLC Clinical Trial page.